“The European Commission proposed the revision of the European pharmaceutical legislation in April. After years of advocating for children with cancer, we want to highlight 4 key points that can make an important difference. This week, Delphine Heenen talks about a big leap forward: the recognition that new cancer drugs developed for adults can be useful for young patients too in a different type of cancer and the obligation to have those drugs tested in children.”
